Introduction
The immunological identification of mesenchymal cells and derived tumors has been greatly aided by the availability of monoclonal antibodies (MAb) to these cell types (1, 3, 4, 15, 35, 39 (8, 17, 18, 21, 23, 26, 34, 36) and normal cells (22) . In general, however, most of the proteins listed above are found in some but not all soft tissue neoplasms or suffer from a lack of specificity as true mesenchymal markers. (2, 12, 13, 28, 30, 32, 38, 40) .
As an extension of these investigations, we now report on the generation of a new MAb, designated LN-6, which is reactive with non-hematopoietic cells of mesenchymal origin and derived neoplastic and benign proliferative diseases. An
MAb that identifies these cell types in routinely processed patho- .9
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. Figure  9 ). Cell surface reactivity was not noted. 
Competition Studies
Competition studies with anti-vimentin and LN-6, using immunofluorescence techniques, revealed partial but not complete dim- 
